19 August 2015, Ann Arbor, Michigan, USA
Preclinical study by independent academic research team provides further evidence that P-188 NF, trademarked as Carmeseal-MD™, conveys its benefits on dystrophic cells by acting as membrane sealant and by decreasing calcium levels and repressing caspase-3 activation and apoptosis.
Phrixus Pharmaceuticals welcomes the results from the preclinical study “Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy.” This study was conducted by independent researchers and examines the effects of Poloxamer-188 NF (P-188 NF) in an in vitro model system comprised of cardiomyocyte stem cells derived from patients with DMD. Treatment of such cells with the membrane sealant P-188 NF significantly decreased the resting cytosolic calcium levels, repressed caspase-3 activation and consequently suppressed apoptosis, all hallmarks of dilated cardiomyopathy in patients with DMD.
This study provides further, independent evidence supporting the hypothesis that P-188 NF acts as a membrane sealant and that it may be useful as a therapeutic agent in patients with DMD.
This study was conducted by researchers in the US and UK with financial support from several non-commercial funding agencies.
Phrixus is currently preparing for a first trial of P-188 NF in patients with DMD with support from the NIH National Heart, Lung, and Blood Institute (NHLBI) in the United States.
Carmeseal-MD is already available in Europe as part of Phrixus’s European Access Program through Phrixus’s European distributor Ethicor Pharma Ltd.
For more information on Carmeseal-MD (P-188 NF), please visit
For more information on the European Access Program for Carmeseal-MD, please visit